COLLEGIUM PHARMACEUTICAL, INC
COLLEGIUM PHARMACEUTICAL, INC (COLL): 26 pipeline candidates · 16 upcoming catalysts · ~18 mo cash runway · 23 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
18.4 months
D/E 4.29 · 24% dilution
Lead: Approved
26 candidates
16 upcoming, next in ~287d
0 buys · 8 sells (180d)
A transparent, data-derived signal for COLLEGIUM PHARMACEUTICAL, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.1B
Cash
$289.6M
Quarterly Burn
$86.3M
Runway
18.4 mo
Revenue
$193.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (26 candidates)
| Drug | Phase |
|---|---|
| 1200mg Cannabidiol | Early Phase 1 |
| 3,4-Methylenedioxymethamphetamine | Phase 2 |
| 400mg Cannabidiol | Early Phase 1 |
| 800mg Cannabidiol | Early Phase 1 |
| Belbuca | Approved |
| Belsomra | N/A |
| Buprenorphine 0.15 MG | Phase 4 |
| Buprenorphine injection | Phase 4 |
| Buprenorphine Pill | Phase 4 |
| Cabotegravir Injection | Phase 4 |
Showing 10 of 26 candidates. Sign up for full pipeline.
Upcoming Catalysts (16)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
264
Total value held
$1.28B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,134,027 | $169.8M |
| janus henderson group plc | 3,651,302 | $120.7M |
| vanguard capital management llc | 2,667,984 | $88.2M |
| fuller & thaler asset management, inc. | 1,499,584 | $49.6M |
| renaissance technologies llc | 1,469,449 | $48.6M |
| state street corp | 1,424,544 | $47.1M |
| eventide asset management, llc | 1,424,282 | $47.1M |
| massachusetts financial services co /ma/ | 1,365,932 | $45.2M |
| principal financial group inc | 1,295,028 | $42.8M |
| rubric capital management lp | 1,279,611 | $42.3M |
Showing top 10 of 264 institutional holders of COLLEGIUM PHARMACEUTICAL, INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in COLLEGIUM PHARMACEUTICAL, INC's pipeline?
COLLEGIUM PHARMACEUTICAL, INC (COLL) has 26 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is COLLEGIUM PHARMACEUTICAL, INC's lead drug candidate?
COLLEGIUM PHARMACEUTICAL, INC's most advanced tracked candidate is 1200mg Cannabidiol (Early Phase 1) for Chronic Pain.
What is COLLEGIUM PHARMACEUTICAL, INC's next catalyst?
COLLEGIUM PHARMACEUTICAL, INC's next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind" — expected April 1, 2027.
What is COLLEGIUM PHARMACEUTICAL, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, COLLEGIUM PHARMACEUTICAL, INC has approximately 18.4 months of cash runway.
What is COLLEGIUM PHARMACEUTICAL, INC's market capitalization?
COLLEGIUM PHARMACEUTICAL, INC's market capitalization is approximately $1.1B.
Get the full picture on COLLEGIUM PHARMACEUTICAL, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.